___

• References:
• 1.Pakniat H, Bahman A, Ansari I. The Relationship of Pregnancy-Associated Plasma Protein A and Human Chorionic Gonadotropin with Adverse Pregnancy Outcomes: A Prospective Study. J Obstet Gynaecol India. 2019; Oct;69(5):412-419.2. Gagnon A, Wilson RD; Society of Obstetricians and Gynaecologists of Canada Genetic Committee. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can. 2008 ;Oct;30(10):918-932.3.Cignini P, Maggio Savasta L, Gulino FA, et al. Predictive value of pregnancy-associated plasma protein-A (PAPP-A) and free beta-hCG on fetal growth restriction: results of a prospective study. Arch Gynecol Obstet. 2016; Jun;293(6):1227-33.4. Zhong Y, Bradshaw R, Stanley AP, Odibo AO. The impact of assisted reproductive technology on the association between first-trimester pregnancy-associated plasma protein a and human chorionic gonadotropin and adverse pregnancy outcomes. Am J Perinatol. 2011; May;28(5):347-545. Smith GCS, Stenhouse EJ, Crossley JA et al. Early Pregnancy Levels of Pregnancy Associated Plasma Protein A and the Risk of Intrauterine Growth Restriction, Premature Birth, Preeclampsia, and Stillbirth. J Clin Endocrinol Metab, April 2002; 87(4):1762–17676. Kagan KO, Wright D, Baker A, et al. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy associated plasma protein. A Ultrasound Obstet Gynecol 2008; 31:618-24.7. Wapner R, Thom E, Simpson JL, et al. First-trimester screening for trisomies 21 and 18 N Engl J Med 2003; 349-15:1405-13.8.Cell-free DNA screening for fetal aneuploidy. Committee Opinion No. 640. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;126(3):e31–79. Leung TY, Sahota DS, Chan LW, Law LW, Fung TY, Leung TN, Lau TK. Prediction of birth weight by fetal crown-rump length and maternal serum levels of pregnancy-associated plasma protein-A in the first trimester. Ultrasound Obstet Gynecol. 2008 Jan;31(1):10-410.Rudenko G, Hohenester E, Muller YA.LG/LNS domains: multiple functions – one business end? Trends Biochem. Sci. 26 ;2001; 363–368.11.Ong Cy, Liao Aw, Spencer K et al. First trimestr maternal serum free bet human chorionic gonadotrophin and pregnancy asociated plasma protein A as a predictors of pregnancy complications. BJOG 2000; 107:1265-70.12. Oxvig C, Sand O, Kristensen T, Gleich GJ, Sottrup-Jensen L. Circulating human pregnancy-associated plasma protein-A is disulfide-brid- ged to the proform of eosinophil major basic protein. J Biol Chem 1993; 268: 12243—12246.13.Brambati B, Lanzani A, Tului L. Ultrasound and biochemical assessment of first trimester of pregnancy. 181—194. In: Chapman M, Gru- dzinskas G, Chard T (Eds): The Embryo: Normal and Abnormal Deve- lopment and Growth. London, Springer Verlag 1990. 4014. Overgaard MZ, Haaning J, Boldt HB, Olsen IM, Laursen LS, Christiansen M et al: Expression of recombinant human pregnancy-associa- ted plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor. J Biol Chem 2000; 275: 31126—31133.15. Bode W, Grams F, Reinemer P, Gomis-Ruth FX, Baumann U, Mc- Kay DB, Stockler W. The metzincin-superfamily of zinc-peptidases. Adv Exp Med Biol 1996; 89: 1-11.16.Kristensen T, Oxvig C, Sand O et al. Amino acid sequence of human pregnancyassociated plasma protein-A derived from cloned cDNA, Biochemistry 33 (1994) 1592– 1598. 17.Haaning J, Oxvig C, Overgaard MT et al. Complete cDNA sequence of the preproform of human pregnancy-associated plasma protein-A: evidence for expressionin the brain and inductionby cAMP, Eur. J. Biochem.1996; 237, 159–163. 18.Boldt HB, Glerup S, Overgaard MT et al. Definition, expression, and characterization of a protein domain in the N-terminus of pregnancy-associated plasma pro-tein-A distantly related to the family of laminin G-like models, Protein Expr. Purif. 48 ,2006; 261–273.19. Francesco O, Cinzia R, A. Allegra, David K, Terrence H, Emanuela O, James M. First trimester screening with free B-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction. Prenatal Diagnosis.2002; 22: 718-72120. Marko N. First trimester screening for down syndrome. Department of Obstetrics and Gynaecology University of Oulu. Acta Univ. Oul. D 727, 2003; 5: 35-41. (URL: http://herkules.oulu.fi/isbn9514270290/)21.Robabeh T, Maryam T, Donya K, Hamed T. Comparison of free beta-HCG and PAPP-A at 12 weeks of gestational age between single pregnancies after spontaneous conception and after IVF treatment. Med Crave. 2017; 8 : 122. Engels MA, Pajkrt E, Groot DT, Schats R, Twisk JW, et al. Validation of correction factors for serum markers for first-trimester Down syndrome screening in singleton pregnancies conceived with assisted reproduction. Fetal Diagn Ther .2013;34(4): 217-224.23. Cavoretto P, Giorgione V, Cipriani S, Viganò P, Candiani M, et al. Nuchal translucency measurement, free β‐hCG and PAPP‐A concentrations in IVF/ICSI pregnancies: systematic review and meta‐analysis. Prenat Diagn.2017; 37(6): 540-555.24. Savasi VM, Mandia L, Laoreti A, Ghisoni L, Duca P, et al. First trimester placental markers in oocyte donation pregnancies. Placenta .2015;36(8): 921-925.25.Smith R, Bischof P, Hughes G, Klopper A. Studies on pregnancy- associated plasma protein A in the third trimester of pregnancy. Brit J Obstet Gynaecol.1979; 86: 882— 887.